Table 1.
Demographic and cancer-related characteristics of survivors for testing Hypotheses 1–2
| Number of survivors (%) |
||
| Age <18 years at baseline and age ≥18 years at 2003FU (Hypothesis 1) | Age ≥18 years at 2003FU (Hypothesis 2) | |
| Total n | 2,022 | 8,383 |
| Sex | ||
| Female | 1,068 (52.8) | 4,252 (50.7) |
| Male | 954 (47.2) | 4,131 (49.3) |
| Race/ethnicitya | ||
| White, non-Hispanic | 1,701 (84.1) | 7,178 (85.6) |
| Non-White | 311 (15.4) | 1,172 (14.0) |
| Cancer diagnosis | ||
| Bone cancer | 20 (1.0) | 738 (8.8) |
| CNS | 200 (9.9) | 887 (10.6) |
| Hodgkin’s disease | 17 (0.8) | 1,142 (13.6) |
| Kidney (Wilms) | 369 (18.2) | 792 (9.4) |
| Leukemia | 924 (45.7) | 2,860 (34.1) |
| Non-Hodgkin’s lymphoma | 77 (3.8) | 652 (7.8) |
| Neuroblastoma | 295 (14.6) | 549 (6.5) |
| Soft tissue sarcoma | 120 (5.9) | 763 (9.1) |
| Cancer treatmentb | ||
| CRT | 528 (26.1) | 2,315 (27.6) |
| IT MTX | 894 (44.2) | 2,838 (33.9) |
| HD Ara-C | 432 (21.4) | 1,185 (14.1) |
| HD MTX | 196 (9.7) | 810 (9.7) |
| Spinal radiation | 121 (6.0) | 575 (6.9) |
| Brain surgery | 182 (9.0) | 797 (9.5) |
| Dexamethasone | 196 (9.7) | 574 (6.8) |
| Age at baseline (years) | ||
| M (SD) | 14.2 (2.2) | 23.9 (7.7) |
| Range | 8–17 | 8–48 |
| Age at 2003FU (years) | ||
| M (SD) | 22.3 (2.2) | 31.6 (7.5) |
| Range | 18–27 | 18–54 |
| Age at cancer diagnosis (years) | ||
| M (SD) | 2.5 (1.9) | 8.0 (5.8) |
| Range | 0–9 | 0–20 |
Note. 2003FU = 2003 follow-up; CNS = central nervous system; CRT = cranial radiation therapy; HD = high dose (≥1,000 mg/m2); IT = intrathecal; MTX = methotrexate.
a
Missing race information: Hypothesis 1 (n = 10) and Hypothesis 2 (n = 33).
b
Some survivors are represented in more than one treatment category. Missing treatment information for survivors without medical chart abstractions: Hypothesis 1 (n = 124) and Hypothesis 2 (n = 706).